Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Epigenetic drug discovery for Alzheimer’s disease
Ramón Cacabelos, Clara Torrellas
Expert Opinion on Drug Discovery (2014) Vol. 9, Iss. 9, pp. 1059-1086
Closed Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Ramón Cacabelos
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 3, pp. 551-551
Open Access | Times Cited: 499
Epigenetic Alterations in Alzheimer’s Disease
José V. Sánchez‐Mut, Johannes Gräff
Frontiers in Behavioral Neuroscience (2015) Vol. 9
Open Access | Times Cited: 161
Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response
Ramón Cacabelos, Clara Torrellas
International Journal of Molecular Sciences (2015) Vol. 16, Iss. 12, pp. 30483-30543
Open Access | Times Cited: 130
The role of pharmacogenomics in adverse drug reactions
Ramón Cacabelos, Natalia Cacabelos, Juan C. Carril
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 5, pp. 407-442
Closed Access | Times Cited: 98
Epigenetics in Alzheimer’s Disease
Xiaodie Gao, Qiang Chen, Hua Yao, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 57
The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress
Ramón Cacabelos, Olaia Martínez-Iglesias, Natalia Cacabelos, et al.
Expert Opinion on Drug Metabolism & Toxicology (2025), pp. 1-28
Closed Access | Times Cited: 1
miR-155 is involved in Alzheimer’s disease by regulating T lymphocyte function
Juhyun Song, Jong Eun Lee
Frontiers in Aging Neuroscience (2015) Vol. 7
Open Access | Times Cited: 80
Sirtuins in Alzheimer’s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics
Ramón Cacabelos, Juan C. Carril, Natalia Cacabelos, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 5, pp. 1249-1249
Open Access | Times Cited: 76
Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years?
Ramón Cacabelos
Expert Opinion on Drug Discovery (2018) Vol. 13, Iss. 6, pp. 523-538
Closed Access | Times Cited: 62
DNA Methylation in Neurodegenerative and Cerebrovascular Disorders
Olaia Martínez-Iglesias, Iván Carrera, Juan C. Carril, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 2220-2220
Open Access | Times Cited: 58
Epigenomic Networking in Drug Development: From Pathogenic Mechanisms to Pharmacogenomics
Ramón Cacabelos
Drug Development Research (2014) Vol. 75, Iss. 6, pp. 348-365
Closed Access | Times Cited: 59
Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases
Óscar Teijido, Ramón Cacabelos
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 10, pp. 3199-3199
Open Access | Times Cited: 57
Alzheimer’s Disease – The Past, the Present and the Future
Benson O. A. Botchway
Science Journal of Clinical Medicine (2017) Vol. 6, Iss. 1, pp. 1-1
Open Access | Times Cited: 55
Resveratrol-salicylate derivatives as selective DNMT3 inhibitors and anticancer agents
Fahad S. Aldawsari, Rodrigo Aguayo‐Ortiz, Kanishk Kapilashrami, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2015) Vol. 31, Iss. 5, pp. 695-703
Open Access | Times Cited: 54
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Ramón Cacabelos
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3059-3059
Open Access | Times Cited: 48
Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease
Ramón Cacabelos
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 8, pp. 673-701
Closed Access | Times Cited: 42
Metabolic disorder in Alzheimer’s disease
Mrinal K. Poddar, Soumyabrata Banerjee, Apala Chakraborty, et al.
Metabolic Brain Disease (2021) Vol. 36, Iss. 5, pp. 781-813
Closed Access | Times Cited: 38
Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer’s disease
Yan Li, Shuxian Lin, Zhicheng Gu, et al.
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 76, pp. 129015-129015
Closed Access | Times Cited: 23
Pharmacogenetic Considerations in the Treatment of Alzheimer’s Disease
Ramón Cacabelos, Clara Torrellas, Óscar Teijido, et al.
Pharmacogenomics (2016) Vol. 17, Iss. 9, pp. 1041-1074
Closed Access | Times Cited: 45
Pharmacogenomics of Alzheimer’s and Parkinson’s diseases
Ramón Cacabelos
Neuroscience Letters (2018) Vol. 726, pp. 133807-133807
Closed Access | Times Cited: 43
The epigenetics of inflammaging: The contribution of age-related heterochromatin loss and locus-specific remodelling and the modulation by environmental stimuli
Christine Nardini, Jean-François Moreau, Noémie Gensous, et al.
Seminars in Immunology (2018) Vol. 40, pp. 49-60
Open Access | Times Cited: 39
Neuroepigenetics of ageing and neurodegeneration-associated dementia: An updated review
Fayaz Ahmad Mir, Ayeman Amanullah, Buddhi Prakash Jain, et al.
Ageing Research Reviews (2023) Vol. 91, pp. 102067-102067
Closed Access | Times Cited: 12
From genome to epigenome: Who is a predominant player in the molecular hallmarks determining epigenetic mechanisms underlying ontogenesis?
M. Samiec, Monika Trzcińska
Reproductive Biology (2024) Vol. 24, Iss. 4, pp. 100965-100965
Open Access | Times Cited: 4
Multitarget Approach for the Treatment of Alzheimer’s Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles
Obdulia Rabal, Juan A. Sánchez‐Arias, Mar Cuadrado‐Tejedor, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 9, pp. 4076-4101
Closed Access | Times Cited: 35
Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer’s Disease
Juan A. Sánchez‐Arias, Obdulia Rabal, Mar Cuadrado‐Tejedor, et al.
ACS Chemical Neuroscience (2016) Vol. 8, Iss. 3, pp. 638-661
Closed Access | Times Cited: 34
Page 1 - Next Page

Scroll to top